2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Hematopoiesis, Immune Mechanism, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, LGL, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4925 Pharmacokinetics, efficacy, and safety of 16 weeks of pegcetacoplan in adolescents with paroxysmal nocturnal hemoglobinuria: Planned interim analysis of an open-label, single-arm, phase 2 trial

Uchendu Uchendu, Luis Lopez Lazaro, MD, PhD2, Veena Selvaratnam, MBBS, FRCPath3
1 Apellis, Inc, a subsidiary of Biogen, Cambridge, Massachusetts, United States
2 Swedish Orphan Biovitrum AB, Stockholm, Sweden
3 Ampang Hospital, Ampang, Malaysia

Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder that leads to increased risk of thrombosis and complement-mediated hemolysis. Approximately 5–10% of PNH cases occur in adolescents; these cases are uniquely challenging because nonspecific symptoms and misdiagnosis, as aplastic anemia, can hinder timely treatment. Furthermore, only 2 of the 6 complement inhibitor treatments available for adults with PNH are currently approved for use in adolescents. Pegcetacoplan, a subcutaneously administered C3 and C3b inhibitor, was approved in 2021 to treat adults with PNH and in 2025 to treat adults and adolescents with the rare glomerular disease C3 glomerulopathy and primary (idiopathic) immune-complex membranoproliferative glomerulonephritis. In this phase 2 trial (NCT04901936), we investigated the pharmacokinetics, efficacy, and safety of pegcetacoplan in adolescents with PNH.

 

Methods: This open-label, single-arm, multicenter trial includes adolescents (12–17 years of age) with anemia due to PNH. Eligible patients were either receiving eculizumab or ravulizumab (switch patients) or were complement inhibitor-naïve (naïve patients). All patients received pegcetacoplan twice weekly at weight-adjusted doses (≥50 kg: 1080 mg; ≥35 to <50 kg: 648 mg first dose, 810 mg thereafter) during the 16-week treatment period. Before the treatment period, switch patients participated in a 4-week run-in period during which pegcetacoplan was added to the prior C5 inhibitor treatment. At the end of the 16-week treatment period, participants had the option to enter an ongoing, long-term extension period. Primary endpoints were pharmacokinetics, efficacy (changes in hemoglobin concentration, lactate dehydrogenase [LDH] concentration, absolute reticulocyte count [ARC]), and safety from baseline to week 16. In this interim analysis, we report efficacy results from naïve patients only because data from the single enrolled switch patient were incomplete.

 

Results: In all, 8 patients (7 naïve, 1 switch) received pegcetacoplan (7 received maintenance dosages of 1080 mg and 1 [naïve] patient received 810 mg twice weekly). The switch patient withdrew from treatment during the 16-week treatment period after week 8 (withdrawal by participant). At data cutoff (January 20, 2026), all 7 naïve patients had completed treatment in the 16-week treatment period. The 7 patients had a mean (SD) age of 16 (0.9) years; 5 (71.4%) were male; 6 (85.7%) were Asian; and the mean (SD) time since PNH diagnosis was 2 (2.6) years. Mean (SD) compliance in the naïve group was 99.6% (1.18%) during the 16-week treatment period. Serum pegcetacoplan concentrations reached steady state approximately 4 to 6 weeks after the first dose. Mean (SD) steady-state concentrations ranged from 607.1 (107.21) to 664.6 (84.00) μg/mL from week 4 to week 16, consistent with data from clinical trials of adults with PNH. From baseline to week 16 in patients with available data, patients with available data had mean (SD) hemoglobin concentration increased from 8.9 (1.81) to 12.6 (1.27) g/dL (change: +3.7 [1.35] g/dL) (n=6), LDH decreased from 2130 (1227.9) to 166 (62.1) U/L (change: –1964 [1227.3] U/L) (n=5), and ARC decreased from 184 (33.4) to 67 (23.4) ×109 cells/L (change: –118 [34.4] ×109 cells/L) (n=6). During the 16-week treatment period, treatment-emergent adverse events (TEAEs) were reported in 3 of 7 (42.9%) treatment-naïve patients, with no TEAEs in the switch patient through the patient’s week 12 follow-up visit. No TEAEs were considered severe, serious, or pegcetacoplan-related. No TEAEs led to drug interruption or discontinuation, dose change, or study discontinuation. No participants in either group had treatment-emergent infections or breakthrough hemolysis (acute hemolysis as determined by the investigator) during the 16-week treatment period. No deaths were reported during the 16-week treatment period.

 

Conclusions: Results through week 16 of this phase 2 trial show that weight-based pegcetacoplan dosing for adolescents with PNH leads to a pharmacokinetic profile equivalent to that of adults. In this small population of adolescent patients with PNH, pegcetacoplan reached steady-state concentrations as early as 4 weeks after the first dose and showed efficacy and safety profiles similar to those reported in the adult population.

Uchendu Uchendu: Apellis (a subsidiary of Biogen) - Stock (publicly traded); Apellis (a subsidiary of Biogen) - Current Employment